Olanzapine: a novel atypical neuroleptic agent.
Reus
V I
VI
Langley Porter Psychiatric Institute, University of California, San Francisco 94143-0984, USA.
D014150:Antipsychotic Agents / Q000009:adverse effects / Q000494:pharmacology* / Q000627:therapeutic use; D001569:Benzodiazepines; D002986:Clinical Trials as Topic; D006801:Humans; D000077152:Olanzapine; D010890:Pirenzepine / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000494:pharmacology / Q000627:therapeutic use; D011618:Psychotic Disorders / Q000188:drug therapy*; D017448:Receptors, Dopamine D2 / Q000187:drug effects; D011985:Receptors, Serotonin / Q000187:drug effects; D012559:Schizophrenia / Q000188:drug therapy
D014150:Antipsychotic Agents; D017448:Receptors, Dopamine D2; D011985:Receptors, Serotonin; D001569:Benzodiazepines; D010890:Pirenzepine; D000077152:Olanzapine